Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
For the six months, sales was INR 1,206.76 million compared to INR 1,691.7 million a year ago. Revenue was INR 1,199.48 million compared to INR 1,765.92 million a year ago. Net loss was INR 269.14 million compared to net income of INR 296.33 million a year ago. Basic loss per share from continuing operations was INR 5.266 compared to basic earnings per share from continuing operations of INR 5.926 a year ago.